These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1023 related items for PubMed ID: 31880796

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials.
    Gotfried MH, Auerbach SH, Dang-Vu TT, Mishima K, Kumar D, Moline M, Malhotra M.
    Drugs Aging; 2024 Sep; 41(9):741-752. PubMed ID: 39120786
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder.
    Moline M, Zammit G, Cheng JY, Perdomo C, Kumar D, Mayleben D.
    J Clin Sleep Med; 2021 Jun 01; 17(6):1167-1174. PubMed ID: 33590823
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T, Soubrane C, Titeux L, Walsh JK, Zoladult Study Group.
    Sleep Med; 2006 Aug 01; 7(5):397-406. PubMed ID: 16815744
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder.
    Arnold V, Ancoli-Israel S, Dang-Vu TT, Mishima K, Pinner K, Malhotra M, Moline M.
    Neurol Ther; 2024 Aug 01; 13(4):1081-1098. PubMed ID: 38748321
    [Abstract] [Full Text] [Related]

  • 16. Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening.
    Murphy P, Kumar D, Zammit G, Rosenberg R, Moline M.
    J Clin Sleep Med; 2020 May 15; 16(5):765-773. PubMed ID: 32022664
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.
    Walsh JK, Soubrane C, Roth T.
    Am J Geriatr Psychiatry; 2008 Jan 15; 16(1):44-57. PubMed ID: 18165461
    [Abstract] [Full Text] [Related]

  • 19. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.
    Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB, Intermezzo Study Group.
    Sleep; 2008 Sep 15; 31(9):1277-84. PubMed ID: 18788653
    [Abstract] [Full Text] [Related]

  • 20. Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia.
    Lalovic B, Savant Landry I, Moline M, Reyderman L, Hussein Z.
    J Clin Pharmacol; 2023 Apr 15; 63(4):498-511. PubMed ID: 36524428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.